Tacrolimus
Tacrolimus is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Tacrolimus; Generic name: TACROLIMUS; Manufacturer: Biocon Pharma Inc..
| Brand name | Tacrolimus |
|---|---|
| Generic name | TACROLIMUS |
| Manufacturer | Biocon Pharma Inc. |
| Used for | 1 INDICATIONS AND USAGE Tacrolimus capsules are calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver, kidney or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney, Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant [ see Clinical Studies (14.1) ] , liver transplants [ see Clinical Studies (14.2) ] and heart transplant [ see Clinical Studies (14.3) ] , and pediatric patients receivin |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Intravenous (IV) use recommended for patients who cannot tolerate oral formulations (capsules). ( 2.1 , 2.2 ) • Administer capsules consistently with or without food. ( 2.1 ) • Therapeutic drug monitoring is recommended. ( 2.1 , 2.6 ) • Avoid eating grapefruit or drinking grapefruit juice. ( 2.1 ) • See dosing adjustments for African-American patients ( 2.2 ), hepatic and renal impaired. ( 2.4 , 2.5 ) • For complete dosing information, see the Full Prescribing Infor |
| Warnings | WARNING - MALIGNANCIES and SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with Tacrolimus or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 ) WARNING: MALIGNANCIES and SERIOUS INFECTIONS See full prescribing information for complete boxed warning Increased risk for developing serious infections and malignancies with Tacrolimus capsules or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 ) |
| Active ingredient(s) | TACROLIMUS |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a557ca9-b1a1-cf8f-a317-e4d8d4d6e60f |